News | March 09, 2022
SII’s Covovax approved for 12-17 years age group
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Covaxin is not approved in the USA for any age group
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Subscribe To Our Newsletter & Stay Updated
